ANAVEX LIFE SCIENCES CORP.
AVXL · XNASCIK 1314052fmd_09BGMACS9C8GX0TPGWS4FPS49DManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Oct 01, 2003 to Jun 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 7 | 5 |
| Research and development | 7 | 11 | 13 | 22 | 25 | 33 | 38 | 44 | 42 | 38 |
| Taxes other than income taxes | – | – | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Selling, general and administrative | – | – | – | – | – | – | – | 12 | 11 | 14 |
| Compensation and benefits | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 16 | 16 | 19 | 29 | (31) | 42 | 51 | 56 | 53 | 51 |
| Operating income | – | – | – | – | (31) | (42) | (51) | (56) | (53) | (51) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 1 | 2 | 2 | 3 | 5 | 4 | 3 | 8 | 10 | 5 |
| Income before taxes | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (47) | (43) | (46) |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) |